Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients

March 2, 2016

Abstract: Untreated opioid dependence adversely affects HIV outcomes. Integrating buprenorphine/naloxone into HIV treatment settings is feasible; however, the optimal level of counseling has not been established. We conducted a 12-week randomized clinical trial of physician management (PM) versus PM plus enhanced medical management (EMM) in 47 subjects. At 12weeks, there were no differences between the […]

Read the full article →

Table of Contents

March 2, 2016

Abstract Field Debates Pros and Cons of Suboxone Taper Using Film Arizona Center with Trauma Focus Moves to Up‐Front Pricing Model Calif. SSA Focuses on New County Financing and Demise of ADP ‘Recovery Wellness Rooms’ Make Presence Known at RNC, DNC This Needs to Change California Legislature Issues Report on Medical Ban in Treatment Programs […]

Read the full article →

Prescription opioid abuse, chronic pain, and primary care: A Co-Occurring Disorders Clinic in the chronic disease model

March 2, 2016

Abstract: Abuse of opioids has become a public health crisis. The historic separation between the addiction and pain communities and a lack of training in medical education have made treatment difficult to provide, especially in primary care. The Co-occurring Disorders Clinic (COD) was established to treat patients with co-morbid chronic pain and addiction. This retrospective […]

Read the full article →

Buprenorphine from detox and beyond: preliminary evaluation of a pilot program to increase heroin dependent individuals' engagement in a full continuum of care

March 2, 2016

Abstract: Absence of successful transition to post-detoxification treatment leads to high rates of relapse among detoxified heroin users. The present study evaluated a pilot buprenorphine treatment program (BTP). Heroin dependent individuals were inducted onto buprenorphine/naloxone in detox, maintained while transitioning through an intensive inpatient program (IIP), and gradually tapered off medication over 5months of outpatient […]

Read the full article →

When the rubber meets the road: Predicting how parity will affect access to substance abuse services and costs

March 2, 2016

This presentation will discuss the likely impacts of Mental Health Parity and Addiction Equity Act on substance abuse treatment services use and costs based on an analysis of health insurance claims and health insurance booklets. The data are from approximately 100 large, self-insured employers and millions of enrollees covering the period 2001–2009. Among the findings […]

Read the full article →

CADTH: Review of opioid dependence treatment guidelines

March 2, 2016

Source: Canadian Agency for Drugs and Technologies in Health (CADTH) Area: News This rapid review by the Canadian Agency for Drugs and Technologies in Health (CADTH) reviews recommendations on the treatment in patients (including pregnant women) with opioid dependence from evidence-based guidelines, with a special interest in the recommendations for treatment of opioid dependence in […]

Read the full article →

Reckitt to discontinue Suboxone tablets in U.S.

March 2, 2016

LONDON (Reuters) – British consumer goods group Reckitt Benckiser is to withdraw its Suboxone heroin treatment tablets in favor of a film version in the United States over the next six months due to the higher risk of children getting hold of the tablets. (Source: Reuters: Health)

Read the full article →

Reckitt withdraws Suboxone over abuse

March 2, 2016

Opioid dependency treatment, a legacy product for the household and personal care company, voluntarily withdrawn in US over increasing signs of abuse of the medicine (Source: FT.com – Drugs and Healthcare)

Read the full article →

Suboxone Maker Pulls Pills in Favor of Film

March 2, 2016

(MedPage Today) — The buprenorphine-naloxone combination product (Suboxone) in sublingual tablet form will soon be pulled from the U.S. market because its child-resistant packaging isn’t effective enough. (Source: MedPage Today Psychiatry)

Read the full article →

Reckitt Benckiser discontinues sale of Suboxone heroin tablets in the US

March 2, 2016

Reckitt Benckiser Pharmaceuticals has voluntarily discontinued the sale of Suboxone tablets, a replacement for heroin dependency, after a report suggested the tablets were more likely to be accidently taken by young children. (Source: Pharmaceutical Technology)

Read the full article →

← Previous Entries

Next Entries →